From Nature to Bedside- Algae Based Bio Compound for Prevention and Treatment of Inflammation, Pain and IBD

Launched by IRCCS SAN RAFFAELE · Sep 15, 2023

Keywords

ClinConnect Summary

This clinical trial, called "From Nature to Bedside," is focused on finding new ways to prevent and treat Inflammatory Bowel Disease (IBD), which includes conditions like Crohn's disease and ulcerative colitis. Researchers are exploring the use of natural compounds extracted from algae, as these may help reduce inflammation and pain associated with IBD. The goal is to discover effective treatments that can improve the quality of life for patients who haven't found relief with existing therapies.

To participate in this study, you need to be an adult aged 18 to 60 who has been diagnosed with ulcerative colitis or Crohn's disease, and you will be undergoing standard endoscopic procedures. There's also a control group for individuals without these conditions who are having similar procedures for other reasons. Participants will be asked to provide informed consent and will undergo tests to evaluate how the algae extracts work in comparison to samples from healthy individuals. While the trial is not yet recruiting, it represents an exciting step toward innovative treatments for IBD.

Gender

ALL

Eligibility criteria

• • INCLUSION CRITERIA
• SUBJECTS WITH THE DIAGNOSIS OF UC OR CD:
• • subjects undergoing endoscopy and biopsies collection per standard of care
• • adult patients ≥18 and \<60 years
• Additionally, for people with UC:
• • - clinical and endoscopic evaluation (Mayo score≥2)
• Additionally, for individuals with CD:
• • - clinical and endoscopic evaluation (Harvey-Bradshaw score ≥5 and overall simplified endoscopic score (SES-CD) \>2)
• SUBJECTS NOT AFFECTED BY UC OR CD:
• • subjects undergoing endoscopy and biopsies collection (≥18 and \<60 years) according to the normal clinical practice (as patients undergoing cancer surveillance, irritable bowel syndrome (IBS), diarrhea)
• • subjects not affected by UC or CD according to the previously reported clinical and endoscopic evaluation criteria All patients will sign the informed consent.
• • EXCLUSION CRITERIA
• SUBJECTS WITH THE DIAGNOSIS OF UC OR CD:
• • - subjects with UC or CD who do not have the previously described clinical and endoscopic evaluation criteria
• SUBJECTS NOT AFFECTED BY UC OR CD (CONTROL GROUP):
• • -subjects undergoing anti-inflammatory and/or immunosuppressive treatments for other diseases not related to UC or CD